Background Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel
treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic …

Immune checkpoint therapy is beneficial for patients with advanced bladder cancer;
however, trials generally exclude patients with comorbidities or uncommon histologies. The …

290 Background: Atezo (anti–PD-L1) has demonstrated safety and efficacy in a broad range
of cancers and is approved in the United States for mUC previously treated with platinum …

323 Background: Atezo is approved in the US for mUC and non-small cell lung cancer after
prior treatment with chemotherapy.> 40% of mUC pts in the Phase 2 IMvigor210 study …

[illus. 1] Cisplatin-based chemotherapy is an effective first-line treatment of patients with
locally advanced or metastatic urothelial carcinoma; however, many patients are ineligible to …

Background: mUC remains a disease with few treatment (tx) options and short OS.
IMvigor210 demonstrated efficacy and safety of atezo (anti–PD-L1) in mUC and led to …

409 Background: IMvigor211 is a global study of atezo vs chemo in platinum-treated mUC.
The study did not meet its primary endpoint of overall survival (OS) in programmed death …

Background First-line treatments for cisplatin-ineligible patients with metastatic urothelial
carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such …

381 Background: Atezo (anti–PD-L1) was the first immune checkpoint inhibitor approved for
mUC. Here, we describe pt characteristics, time on tx (TOT) and distribution of tx cycles for …

Objectives Although the treatment strategy for advanced urothelial carcinoma (aUC) has
drastically changed since pembrolizumab was introduced in 2017, studies revealing current …